Millipore Sigma Vibrant Logo

530070 Pristimerin - CAS 1258-84-0 - Calbiochem

A cell-permeable plant dienone-phenolic triterpenoid, naturally isolated from tripterygium wilfordii.

Pristimerin - CAS 1258-84-0 - Calbiochem: のSDS（安全データシート）、CoA（試験成績書）およびCoQ（品質証明書）、カタログなど製品関連の技術資料を入手いただけます。

同義語: Monoacylglycerol Lipase Inhibitor II, Proteasome Inhibitor XV, NF-κB Activation Inhibitor IX, MAGL Inhibitor II

View This Product on Sigma-Aldrich
530070
価格＆在庫状況を照会

概要

Replacement Information

主要スペック表

CAS #Empirical Formula
1258-84-0C₃₀H₄₀O₄

価格＆在庫状況

カタログ番号 在庫状況包装 Qty/Pk 価格 数量
530070-5MGCN
在庫状況検索中…
—
現在国内在庫なし 現在国内在庫なし
現在国内在庫有り 
販売中止
在庫僅少
現在国内在庫あり
    Remaining : Will advise
      Remaining : Will advise
      注文対象外
      お問合せください
      Contact Customer Service

      		 樹脂ｱﾝﾌﾟﾙ 5 mg
      価格を検索中…
      価格が見つかりません
      Minimum Quantity needs to be mulitiple of
      Maximum Quantity is
      弊社照会 詳細を表示　
      値引
      ()
       
      —
      弊社照会
      		 —
      Description
      OverviewA cell-permeable plant dienone-phenolic triterpenoid, naturally isolated from tripterygium wilfordii, whose inhibitory activities against proteasome chymotrypsin subunit (IC50 = 2.2 and 3.0 µM against purified rabbit 20S and human 26S proteasome, respectively) and cellular NF-κB pathway/IKK activation most likely account for its reported anticancer efficacy both in vitro (IC50 ≤610 nM in A549, K562, KBM5, MCF-7, MDA-MB-231, HepG2, and primary human leukemia cell cultures) and in mice in vivo (1 to 2.5 mg/kg/day, s.c.), including imatinib/STI571-resistant cancer cells harboring Bcr-Abl T315I mutation. Also reported to inhibit the activity of monoacylglycerol lipase (MGL), the enzyme that hydrolyzes and deactivates the cannabionoid receptor ligand 2-Arachidonoyl-sn-glycerol (2-AG), in a reversible manner with high potency (IC50 = 93 nM).
      Catalogue Number530070
      Brand Family Calbiochem®
      SynonymsMonoacylglycerol Lipase Inhibitor II, Proteasome Inhibitor XV, NF-κB Activation Inhibitor IX, MAGL Inhibitor II
      References
      ReferencesLu, Z., et al. 2010. Mol. Cancer 9, 112.
      King, A.R., et al. 2009. Chem. Biol. 16, 1045.
      Tiedemann, R.E., et al. 2009. Blood 113, 4027.
      Yang, H., et al. 2008. J. Cell. Biochem. 103, 234.
      Wu, C.C., et al. 2005. Mol. Cancer Ther. 4, 1277.
      Product Information
      CAS number1258-84-0
      FormRed solid
      Hill FormulaC₃₀H₄₀O₄
      Chemical formulaC₃₀H₄₀O₄
      Structure formula ImageStructure formula Image
      Quality LevelMQ100
      Applications
      Biological Information
      Purity≥95% by HPLC
      Physicochemical Information
      Dimensions
      Materials Information
      Toxicological Information
      Safety Information according to GHS
      Safety Information
      S PhraseS: 20-24/25-36/37/39

      When using do not eat or drink.
      Avoid contact with skin and eyes.
      Wear suitable protective clothing, gloves and eye/face protection.
      Product Usage Statements
      Storage and Shipping Information
      Ship Code Ambient Temperature Only
      Toxicity Standard Handling
      Storage +2°C to +8°C
      Protect from Light Protect from light
      Do not freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Packaging Information
      Packaged under inert gas Packaged under inert gas
      Transport Information
      Supplemental Information
      Specifications
      Global Trade Item Number
      カタログ番号 GTIN
      530070-5MGCN 04055977269352

      Documentation

      Pristimerin - CAS 1258-84-0 - Calbiochem (M)SDS

      タイトル

      英語版製品安全データシート（(M)SDS） 

      Pristimerin - CAS 1258-84-0 - Calbiochem 試験成績書（CoA）

      タイトルロット番号
      530070

      参考資料

      参考資料の概要
      Lu, Z., et al. 2010. Mol. Cancer 9, 112.
      King, A.R., et al. 2009. Chem. Biol. 16, 1045.
      Tiedemann, R.E., et al. 2009. Blood 113, 4027.
      Yang, H., et al. 2008. J. Cell. Biochem. 103, 234.
      Wu, C.C., et al. 2005. Mol. Cancer Ther. 4, 1277.
      データシート

      Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

      Revision09-August-2010 RFH
      SynonymsMonoacylglycerol Lipase Inhibitor II, Proteasome Inhibitor XV, NF-κB Activation Inhibitor IX, MAGL Inhibitor II
      DescriptionA cell-permeable plant dienone-phenolic triterpenoid, naturally isolated from tripterygium wilfordii, whose inhibitory activities against proteasome chymotrypsin subunit (IC50 = 2.2 and 3.0 µM against purified rabbit 20S and human 26S proteasome, respectively) and cellular NF-κB pathway/IKK activation most likely account for its reported anticancer efficacy both in vitro (IC50 ≤610 nM in A549, K562, KBM5, MCF-7, MDA-MB-231, HepG2, and primary human leukemia cell cultures) and in mice in vivo (1 to 2.5 mg/kg/day, s.c.), including imatinib/STI571-resistant cancer cells harboring Bcr-Abl T315I mutation. Also reported to inhibit the activity of monoacylglycerol lipase (MGL), the enzyme that hydrolyzes and deactivates the cannabionoid receptor ligand 2-Arachidonoyl-sn-glycerol (2-AG), in a reversible manner with high potency (IC50 = 93 nM).
      FormRed solid
      Intert gas (Yes/No) Packaged under inert gas
      CAS number1258-84-0
      Chemical formulaC₃₀H₄₀O₄
      Structure formulaStructure formula
      Purity≥95% by HPLC
      SolubilityDMSO (10 mg/ml) or Ethanol (2.5 mg/ml)
      Storage Protect from light
      +2°C to +8°C
      Do Not Freeze Ok to freeze
      Special InstructionsFollowing reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.
      Toxicity Standard Handling
      ReferencesLu, Z., et al. 2010. Mol. Cancer 9, 112.
      King, A.R., et al. 2009. Chem. Biol. 16, 1045.
      Tiedemann, R.E., et al. 2009. Blood 113, 4027.
      Yang, H., et al. 2008. J. Cell. Biochem. 103, 234.
      Wu, C.C., et al. 2005. Mol. Cancer Ther. 4, 1277.